Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug

Jixun Dai, Chandanamalie Punchihewa, Prakash Mistry, Aik Teong Ooi, Danzhou Yang

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The new bisphenazine anticancer drug MLN944 is a novel cytotoxic agent with exceptional anti-tumor activity against a range of human and murine tumor models both in vitro and in vivo. MLN944 has recently entered Phase I clinical trials. Despite the structural similarity with its parent monophenazine carboxamide and acridine carboxamide anticancer compounds, MLN944 appears to work by a distinct mechanism of inhibiting DNA transcription rather than the expected mechanism of topoisomerase I and II inhibition. Here we present the first NMR structure of MLN944 complexed with d(ATG-CAT)2 DNA duplex, demonstrating a novel binding mode in which the two phenazine rings bis-intercalate at the 5′-TpG site, with the carboxamide amino linker lying in the major groove of DNA. The MLN944 molecule adopts a significantly unexpected conformation and side chain orientation in the DNA complex, with the N10 on the phenazine ring protonated at pH 7. The phenazine chromophore of MLN944 is very well stacked with the flanking DNA base pairs using the parallel base-stacking intercalation binding mode. The DNA sequence specificity and the groove recognition of MLN944 binding is determined by several site-specific hydrogen bond interactions with the central G:C base pair as well as the favorable stacking interactions with the 5′-flanking thymine. The specific binding site of MLN944 is known to be recognized by a number of important transcription factors. Our electrophoretic gel mobility shift assay results demonstrated that the c-Jun DNA binding to the AP-1 site is significantly inhibited by MLN944 in a dose-dependent manner. Thus, the exceptional biological activity of MLN944 may be due to its novel DNA binding mode leading to a unique mechanism of action.

Original languageEnglish (US)
Pages (from-to)46096-46103
Number of pages8
JournalJournal of Biological Chemistry
Volume279
Issue number44
DOIs
StatePublished - Oct 29 2004

Fingerprint

Intercalation
DNA
Pharmaceutical Preparations
Base Pairing
Tumors
MLN 944
Acridines
Type II DNA Topoisomerase
Type I DNA Topoisomerase
Clinical Trials, Phase I
Thymine
DNA sequences
Cytotoxins
Transcription Factor AP-1
Electrophoretic Mobility Shift Assay
Transcription
Chromophores
Bioactivity
Crystal orientation
Conformations

ASJC Scopus subject areas

  • Biochemistry

Cite this

Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug. / Dai, Jixun; Punchihewa, Chandanamalie; Mistry, Prakash; Ooi, Aik Teong; Yang, Danzhou.

In: Journal of Biological Chemistry, Vol. 279, No. 44, 29.10.2004, p. 46096-46103.

Research output: Contribution to journalArticle

Dai, Jixun ; Punchihewa, Chandanamalie ; Mistry, Prakash ; Ooi, Aik Teong ; Yang, Danzhou. / Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug. In: Journal of Biological Chemistry. 2004 ; Vol. 279, No. 44. pp. 46096-46103.
@article{3cb5a42ab3cf4b40ab10ac963f88071a,
title = "Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug",
abstract = "The new bisphenazine anticancer drug MLN944 is a novel cytotoxic agent with exceptional anti-tumor activity against a range of human and murine tumor models both in vitro and in vivo. MLN944 has recently entered Phase I clinical trials. Despite the structural similarity with its parent monophenazine carboxamide and acridine carboxamide anticancer compounds, MLN944 appears to work by a distinct mechanism of inhibiting DNA transcription rather than the expected mechanism of topoisomerase I and II inhibition. Here we present the first NMR structure of MLN944 complexed with d(ATG-CAT)2 DNA duplex, demonstrating a novel binding mode in which the two phenazine rings bis-intercalate at the 5′-TpG site, with the carboxamide amino linker lying in the major groove of DNA. The MLN944 molecule adopts a significantly unexpected conformation and side chain orientation in the DNA complex, with the N10 on the phenazine ring protonated at pH 7. The phenazine chromophore of MLN944 is very well stacked with the flanking DNA base pairs using the parallel base-stacking intercalation binding mode. The DNA sequence specificity and the groove recognition of MLN944 binding is determined by several site-specific hydrogen bond interactions with the central G:C base pair as well as the favorable stacking interactions with the 5′-flanking thymine. The specific binding site of MLN944 is known to be recognized by a number of important transcription factors. Our electrophoretic gel mobility shift assay results demonstrated that the c-Jun DNA binding to the AP-1 site is significantly inhibited by MLN944 in a dose-dependent manner. Thus, the exceptional biological activity of MLN944 may be due to its novel DNA binding mode leading to a unique mechanism of action.",
author = "Jixun Dai and Chandanamalie Punchihewa and Prakash Mistry and Ooi, {Aik Teong} and Danzhou Yang",
year = "2004",
month = "10",
day = "29",
doi = "10.1074/jbc.M404053200",
language = "English (US)",
volume = "279",
pages = "46096--46103",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "44",

}

TY - JOUR

T1 - Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug

AU - Dai, Jixun

AU - Punchihewa, Chandanamalie

AU - Mistry, Prakash

AU - Ooi, Aik Teong

AU - Yang, Danzhou

PY - 2004/10/29

Y1 - 2004/10/29

N2 - The new bisphenazine anticancer drug MLN944 is a novel cytotoxic agent with exceptional anti-tumor activity against a range of human and murine tumor models both in vitro and in vivo. MLN944 has recently entered Phase I clinical trials. Despite the structural similarity with its parent monophenazine carboxamide and acridine carboxamide anticancer compounds, MLN944 appears to work by a distinct mechanism of inhibiting DNA transcription rather than the expected mechanism of topoisomerase I and II inhibition. Here we present the first NMR structure of MLN944 complexed with d(ATG-CAT)2 DNA duplex, demonstrating a novel binding mode in which the two phenazine rings bis-intercalate at the 5′-TpG site, with the carboxamide amino linker lying in the major groove of DNA. The MLN944 molecule adopts a significantly unexpected conformation and side chain orientation in the DNA complex, with the N10 on the phenazine ring protonated at pH 7. The phenazine chromophore of MLN944 is very well stacked with the flanking DNA base pairs using the parallel base-stacking intercalation binding mode. The DNA sequence specificity and the groove recognition of MLN944 binding is determined by several site-specific hydrogen bond interactions with the central G:C base pair as well as the favorable stacking interactions with the 5′-flanking thymine. The specific binding site of MLN944 is known to be recognized by a number of important transcription factors. Our electrophoretic gel mobility shift assay results demonstrated that the c-Jun DNA binding to the AP-1 site is significantly inhibited by MLN944 in a dose-dependent manner. Thus, the exceptional biological activity of MLN944 may be due to its novel DNA binding mode leading to a unique mechanism of action.

AB - The new bisphenazine anticancer drug MLN944 is a novel cytotoxic agent with exceptional anti-tumor activity against a range of human and murine tumor models both in vitro and in vivo. MLN944 has recently entered Phase I clinical trials. Despite the structural similarity with its parent monophenazine carboxamide and acridine carboxamide anticancer compounds, MLN944 appears to work by a distinct mechanism of inhibiting DNA transcription rather than the expected mechanism of topoisomerase I and II inhibition. Here we present the first NMR structure of MLN944 complexed with d(ATG-CAT)2 DNA duplex, demonstrating a novel binding mode in which the two phenazine rings bis-intercalate at the 5′-TpG site, with the carboxamide amino linker lying in the major groove of DNA. The MLN944 molecule adopts a significantly unexpected conformation and side chain orientation in the DNA complex, with the N10 on the phenazine ring protonated at pH 7. The phenazine chromophore of MLN944 is very well stacked with the flanking DNA base pairs using the parallel base-stacking intercalation binding mode. The DNA sequence specificity and the groove recognition of MLN944 binding is determined by several site-specific hydrogen bond interactions with the central G:C base pair as well as the favorable stacking interactions with the 5′-flanking thymine. The specific binding site of MLN944 is known to be recognized by a number of important transcription factors. Our electrophoretic gel mobility shift assay results demonstrated that the c-Jun DNA binding to the AP-1 site is significantly inhibited by MLN944 in a dose-dependent manner. Thus, the exceptional biological activity of MLN944 may be due to its novel DNA binding mode leading to a unique mechanism of action.

UR - http://www.scopus.com/inward/record.url?scp=8544273289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544273289&partnerID=8YFLogxK

U2 - 10.1074/jbc.M404053200

DO - 10.1074/jbc.M404053200

M3 - Article

C2 - 15317822

AN - SCOPUS:8544273289

VL - 279

SP - 46096

EP - 46103

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 44

ER -